(113) Profile of Antihypertensive Class Drug Usage in Post-Myocardial Infarction Patients in a General Hospital in Banjarmasin During 2016-2020

Sunday, August 28, 2022

8:00 AM – 1:45 PM CEST

Location: Hall C

Publication Number: 1158

Presenting Author(s)

Pandji Winata Nurikhwan
– dr., School of Medicine Lambung Mangkurat University, Banjarmasin, Kalimantan Selatan, Indonesia

Co-Author(s)

Djallalluddin Djallalluddin
– Department of Internal Medicine, Faculty of Medicine, Universitas Lambung Mangkurat, Indonesia
Muhammad Nu'man Akmal
– Medicine Study Program, Faculty of Medicine, Universitas Lambung Mangkurat, Indonesia
Alfi Yasmina
– School of Medicine Lambung Mangkurat University, Banjarmasin, Kalimantan Selatan, Indonesia
Dwi Laksono Adiputro
– Department of Cardiology, Faculty of Medicine, Universitas Lambung Mangkurat, Indonesia

Background: Antihypertensive class drugs are recommended for myocardial infarction patients to prevent major adverse cardiovascular events.

Objectives: This study was aimed to determine the profile of antihypertensive class drug usage in post-myocardial infarction patients in a general hospital in Banjarmasin during 2016-2020, both for whole antihypertensives and for individual classes, and based patients’ age and comorbidities.

Methods: This was a drug utilization study using a descriptive design, with data sources from electronic medical records of myocardial infarction patients in general hospital in Banjarmasin during 2016-2020. Descriptive analysis was conducted on the antihypertensive drug usage as a whole, and based on age and the history of hypertension, diabetes mellitus, chronic renal failure, and heart failure.

Results: There were 887 MI patients included, with most patients were under 60 years old (62.8%), with a history of comorbidities including hypertension (4.7%), diabetes (11.2%), chronic renal failure (1.4%), and heart failure (3.5%). All myocardial infarction patients received a combination of antihypertensive class drugs. β-blockers and calcium channel blockers (CCBs) were given to all patients. Diuretics were the third highest antihypertensive drugs given, followed by angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs). Based on patients’ age, those with age ≥ 65 years received more ARBs and diuretics. Patients with a history of hypertension and diabetes mellitus were more likely to receive ARBs and diuretics. Patients with a history of chronic kidney failure were less often received ACE-Is, ARBs, and diuretics, while patients with a history of heart failure were more likely to receive ACE-Is, ARBs, and diuretics.

Conclusions: It can be concluded that the use of drugs from antihypertensive classes after myocardial infarction in a general hospital in Banjarmasin during 2016-2020 mostly has followed the treatment guideline.